Copy to clipboard 
SI-BONE reported 1Q26 orthopedic sales of $52.6 million, up 11.2% compared to the first quarter of 2025.
To date, the company has completed nearly 150,000 procedures across three disease states focused on the sacroiliac joint. In the first quarter, the company had over 1,650 active surgeons, a 17% increase year-over-year. Only 25% of SI-BONE’s surgeons performing SI joint fusion use the platform across additional indications, underscoring a significant opportunity to expand.
“Taken together, we made significant progress toward building a durable growth engine with record physician engagement, a broadening procedural footprint, expanding commercial scale and favorable reimbursement backdrop,” said SI-BONE CEO Laura Francis. “This gives us confidence that we’re positioned to accelerate our revenue growth going forward.”
The company’s trauma partnership with Smith+Nephew remains in its early stages, but is targeting a total addressable market of 60,000 procedures worth an estimated $300 million annually.
SI-BONE now expects 2026 sales between $230 million and $233 million, representing growth between 14% and 16%
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 1Q26 | 1Q25 | $ Chg | % Chg |
|---|---|---|---|---|
| Spine | $52.6 | $47.3 | $5.3 | 11.2% |
Orthopedic Sales by Geography
| Region | 1Q26 | 1Q25 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $49.3 | $44.8 | $4.5 | 10% |
| OUS | $3.3 | $2.5 | $0.8 | 33.9% |
| Total | $52.6 | $47.3 | $5.3 | 11.2% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $52.6 | |
| Cost of Sales | $10.6 | 20.2% |
| Sales and Marketing | $32.8 | 62.4% |
| General and Admin | $10.0 | 19.1% |
| R & D | $4.2 | 8% |
| Other | ($0.8) | (1.4%) |
| Net Earnings | ($4.3) | (8.2%) |
SI-BONE reported 1Q26 orthopedic sales of $52.6 million, up 11.2% compared to the first quarter of 2025.
To date, the company has completed nearly 150,000 procedures across three disease states focused on the sacroiliac joint. In the first quarter, the company had over 1,650 active surgeons, a 17% increase year-over-year. Only 25% of...
SI-BONE reported 1Q26 orthopedic sales of $52.6 million, up 11.2% compared to the first quarter of 2025.
To date, the company has completed nearly 150,000 procedures across three disease states focused on the sacroiliac joint. In the first quarter, the company had over 1,650 active surgeons, a 17% increase year-over-year. Only 25% of SI-BONE’s surgeons performing SI joint fusion use the platform across additional indications, underscoring a significant opportunity to expand.
“Taken together, we made significant progress toward building a durable growth engine with record physician engagement, a broadening procedural footprint, expanding commercial scale and favorable reimbursement backdrop,” said SI-BONE CEO Laura Francis. “This gives us confidence that we’re positioned to accelerate our revenue growth going forward.”
The company’s trauma partnership with Smith+Nephew remains in its early stages, but is targeting a total addressable market of 60,000 procedures worth an estimated $300 million annually.
SI-BONE now expects 2026 sales between $230 million and $233 million, representing growth between 14% and 16%
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 1Q26 | 1Q25 | $ Chg | % Chg |
|---|---|---|---|---|
| Spine | $52.6 | $47.3 | $5.3 | 11.2% |
Orthopedic Sales by Geography
| Region | 1Q26 | 1Q25 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $49.3 | $44.8 | $4.5 | 10% |
| OUS | $3.3 | $2.5 | $0.8 | 33.9% |
| Total | $52.6 | $47.3 | $5.3 | 11.2% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $52.6 | |
| Cost of Sales | $10.6 | 20.2% |
| Sales and Marketing | $32.8 | 62.4% |
| General and Admin | $10.0 | 19.1% |
| R & D | $4.2 | 8% |
| Other | ($0.8) | (1.4%) |
| Net Earnings | ($4.3) | (8.2%) |
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
